IMNM Immunome Inc

Price (delayed)

$14.82

Market cap

$888.74M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.55

Enterprise value

$620.12M

Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are ...

Highlights
The equity has soared by 138% from the previous quarter
Immunome's quick ratio has surged by 59% QoQ
IMNM's net income has dropped by 117% since the previous quarter
IMNM's EPS is down by 40% QoQ

Key stats

What are the main financial stats of IMNM
Market
Shares outstanding
59.97M
Market cap
$888.74M
Enterprise value
$620.12M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.1
Price to sales (P/S)
60.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
48.89
Earnings
Revenue
$12.68M
EBIT
-$232.03M
EBITDA
-$231.19M
Free cash flow
-$45.8M
Per share
EPS
-$7.55
Free cash flow per share
-$0.89
Book value per share
$4.78
Revenue per share
$0.25
TBVPS
$6.2
Balance sheet
Total assets
$319.75M
Total liabilities
$34.18M
Debt
$1.21M
Equity
$285.57M
Working capital
$282.56M
Liquidity
Debt to equity
0
Current ratio
10.18
Quick ratio
10.07
Net debt/EBITDA
1.16
Margins
EBITDA margin
-1,822.8%
Gross margin
100%
Net margin
-1,829.4%
Operating margin
-1,871.5%
Efficiency
Return on assets
-153.9%
Return on equity
-220.5%
Return on invested capital
-16,945.6%
Return on capital employed
-80.3%
Return on sales
-1,829.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IMNM stock price

How has the Immunome stock price performed over time
Intraday
7.7%
1 week
1.09%
1 month
19.13%
1 year
108.15%
YTD
38.5%
QTD
22.48%

Financial performance

How have Immunome's revenue and profit performed over time
Revenue
$12.68M
Gross profit
$12.68M
Operating income
-$237.36M
Net income
-$232.03M
Gross margin
100%
Net margin
-1,829.4%
Immunome's operating margin has plunged by 140% from the previous quarter and by 49% YoY
IMNM's net margin has dropped by 140% since the previous quarter and by 47% year-on-year
IMNM's net income has dropped by 117% since the previous quarter
Immunome's operating income has shrunk by 117% QoQ

Growth

What is Immunome's growth rate over time

Valuation

What is Immunome stock price valuation
P/E
N/A
P/B
3.1
P/S
60.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
48.89
IMNM's EPS is down by 40% QoQ
The equity has soared by 138% from the previous quarter
The price to book (P/B) is 68% lower than the last 4 quarters average of 9.0
IMNM's price to sales (P/S) is 60% higher than its last 4 quarters average of 35.0
The revenue fell by 10% QoQ

Efficiency

How efficient is Immunome business performance
IMNM's ROS has shrunk by 140% QoQ and by 47% YoY
The company's return on assets has shrunk by 81% YoY and by 19% QoQ
Immunome's ROE has plunged by 53% YoY but it has increased by 23% from the previous quarter

Dividends

What is IMNM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMNM.

Financial health

How did Immunome financials performed over time
The total assets has soared by 115% from the previous quarter
Immunome's quick ratio has surged by 59% QoQ
IMNM's debt is 100% smaller than its equity
The equity has soared by 138% from the previous quarter
Immunome's debt to equity has plunged by 100% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.